Hemorrhoids are the most common ailment affecting the male gender. This condition affects 38.93% of the general population and is even more common in middle aged individuals with higher social-economic status. It is estimated that at least half this population is affected by hemorrhoids at least once in their lifetime. Topical hemorrhoid therapy is the most frequently prescribed first line treatment by the general practitioner and is the most common type of therapy sought by the patient in the beginning stages. There have been no documented randomized clinical studies that observed the quality and success of using perianal lidocaine as treatment and therefore this method is based on empirical findings without any quality clinical proof. We can state that the topical treatment of hemorrhoids is not a medically founded pharmacologic practice, but rather, remains an empirically based treatment without proof of effectiveness. In the American Gastroenterological Association guidelines for diagnosing and treating hemorrhoids, under the topical treatment section, the following is stated: Over the counter topical and suppository products have become more present in the empirical treatment of symptoms associated with hemorrhoids, without any information supporting their use. The goal of this study is to conduct a randomized clinical study on the effectiveness of using local lidocaine compared with a placebo in reducing hemorrhoid symptoms. The main goal is to determine the effectiveness of topical lidocaine use in patients with symptomatic hemorrhoids who, due to this ailment, have changes in the degree of disease and changes/increase in symptoms (pain, itch, bleeding, swelling and comfort are subjective symptoms which we observed and objectified using the validated analogue Corrects scale) The results of this study show that lidocaine, when used as a topical treatment has the identical effect on symptoms using the Corrects scale on days 1,3 and 7 after application as the placebo. If we stratify the individual symptoms such as pail, itch, swelling, bleeding and comfort, we see that lidocaine when compared with the placebo is not effective in reducing hemorrhoid symptoms. Furthermore, there is no significant difference in the general patients’ health status nor on the subjective decrease in symptoms between the two groups at 1,3 and 7 days after topical application. In both groups there was no noted improvement in the degree of disease and therefore we can conclude that neither lidocaine nor the placebo can influence the morphologic changes in hemorrhoid tissue.